Taplin ME - Search Results

1

The DHEA-sulfate depot following P450c17 inhibition supports the case for AKR1C3 inhibition in high risk localized and advanced castration resistant prostate cancer.

Tamae D, Mostaghel E, Montgomery B, Nelson PS, Balk SP, Kantoff PW, Taplin ME, Penning TM. Tamae D, et al. Among authors: taplin me. Chem Biol Interact. 2015 Jun 5;234:332-8. doi: 10.1016/j.cbi.2014.12.012. Epub 2014 Dec 13. Chem Biol Interact. 2015. PMID: 25514466 Free PMC article. Review.

2

Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer.

Taplin ME, Bubley GJ, Shuster TD, Frantz ME, Spooner AE, Ogata GK, Keer HN, Balk SP. Taplin ME, et al. N Engl J Med. 1995 May 25;332(21):1393-8. doi: 10.1056/NEJM199505253322101. N Engl J Med. 1995. PMID: 7723794 Free article.

3

Evidence against T-cell development in the adult human intestinal mucosa based upon lack of terminal deoxynucleotidyltransferase expression.

Taplin ME, Frantz ME, Canning C, Ritz J, Blumberg RS, Balk SP. Taplin ME, et al. Immunology. 1996 Mar;87(3):402-7. doi: 10.1046/j.1365-2567.1996.496571.x. Immunology. 1996. PMID: 8778025 Free PMC article.

4

High dose bicalutamide for androgen independent prostate cancer: effect of prior hormonal therapy.

Joyce R, Fenton MA, Rode P, Constantine M, Gaynes L, Kolvenbag G, DeWolf W, Balk S, Taplin ME, Bubley GJ. Joyce R, et al. Among authors: taplin me. J Urol. 1998 Jan;159(1):149-53. doi: 10.1016/s0022-5347(01)64039-4. J Urol. 1998. PMID: 9400459

5

Functional characterization of mutant androgen receptors from androgen-independent prostate cancer.

Fenton MA, Shuster TD, Fertig AM, Taplin ME, Kolvenbag G, Bubley GJ, Balk SP. Fenton MA, et al. Among authors: taplin me. Clin Cancer Res. 1997 Aug;3(8):1383-8. Clin Cancer Res. 1997. PMID: 9815822

6

Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist.

Taplin ME, Bubley GJ, Ko YJ, Small EJ, Upton M, Rajeshkumar B, Balk SP. Taplin ME, et al. Cancer Res. 1999 Jun 1;59(11):2511-5. Cancer Res. 1999. PMID: 10363963

7

Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663.

Taplin ME, Rajeshkumar B, Halabi S, Werner CP, Woda BA, Picus J, Stadler W, Hayes DF, Kantoff PW, Vogelzang NJ, Small EJ; Cancer and Leukemia Group B Study 9663. Taplin ME, et al. J Clin Oncol. 2003 Jul 15;21(14):2673-8. doi: 10.1200/JCO.2003.11.102. J Clin Oncol. 2003. PMID: 12860943 Clinical Trial.

8

The ingredients for prostate cancer nomograms: the addition of biomarkers sets the table for future recipes.

Taplin ME, Kantoff PW. Taplin ME, et al. J Clin Oncol. 2003 Oct 1;21(19):3552-3. doi: 10.1200/JCO.2003.07.083. Epub 2003 Aug 11. J Clin Oncol. 2003. PMID: 12913104 No abstract available.

9

Androgen receptor: a key molecule in the progression of prostate cancer to hormone independence.

Taplin ME, Balk SP. Taplin ME, et al. J Cell Biochem. 2004 Feb 15;91(3):483-90. doi: 10.1002/jcb.10653. J Cell Biochem. 2004. PMID: 14755679 Review.

10

Prognostic significance of plasma chromogranin a levels in patients with hormone-refractory prostate cancer treated in Cancer and Leukemia Group B 9480 study.

Taplin ME, George DJ, Halabi S, Sanford B, Febbo PG, Hennessy KT, Mihos CG, Vogelzang NJ, Small EJ, Kantoff PW. Taplin ME, et al. Urology. 2005 Aug;66(2):386-91. doi: 10.1016/j.urology.2005.03.040. Urology. 2005. PMID: 16098367

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

219 results

Search Page